帕博利珠单抗治疗活动性脑转移黑色素瘤患者的长期生存:一项II期试验
这项II期试验纳入23例有未治疗无症状5-20mm脑转移的黑色素瘤患者,接受帕博利珠单抗治疗最多24个月。6例(26%)达脑转移缓解,中位无进展生存2个月、总生存17个月,24个月时11例(48%)存活。结论认为帕博利珠单抗在黑色素瘤脑转移中有活性、毒性可接受且缓解持久。
要点
- 23例未治疗无症状5-20mm脑转移黑色素瘤患者中,6例(26%)达脑转移缓解。
- 中位无进展生存2个月,中位总生存17个月,24个月时11例(48%)存活。
- 神经系统不良事件发生率65%,除1例外均为1-2级;3例出现癫痫发作并用抗惊厥药治疗。
核心结论
- 帕博利珠单抗在黑色素瘤脑转移中有活性,毒性可接受且缓解持久。
- 脑转移与颅外缓解一致,支持使用帕博利珠单抗治疗小的无症状脑转移。
- 2年生存率与接受抗程序性死亡1(PD-1)药物治疗的无脑转移患者相似。
研究设计与样本
- II期临床试验(ClinicalTrials.gov标识符:NCT02085070),纳入23例有1个或多个无症状、未治疗、5-20mm且不需皮质类固醇的脑转移黑色素瘤患者。
- 70%患者既往接受过全身治疗;帕博利珠单抗给药最多24个月。
- 主要终点为脑转移缓解,采用改良实体瘤疗效评价标准(RECIST)评估;对治疗前肿瘤分析T细胞浸润和程序性死亡配体1表达。
主要发现
- 6例患者(26%)达脑转移缓解;8例患者(35%)因进展或需放疗未达方案评估扫描,无法评估脑转移缓解。
- 脑转移与全身缓解一致,所有持续缓解在24个月时仍维持。
- 中位无进展生存期和总生存期分别为2个月和17个月;24个月时11例(48%)存活,包括3例不可评估患者。
- 3例不可评估患者中,1例出血、2例因病灶周围水肿症状需放射外科治疗,但3例均在24个月后继续使用商业帕博利珠单抗。
- 24个月存活者均未接受后续BRAF抑制剂;神经系统不良事件发生率65%,除1例外均为1级或2级,3例出现癫痫发作并用抗惊厥药治疗。
关键数值与推荐
- 脑转移缓解定义为按改良RECIST评估的缓解,6例(26%)达缓解。
- 中位无进展生存期2个月,中位总生存期17个月,24个月生存率48%(11例)。
- 神经系统不良事件发生率65%,除1例外均为1级或2级。
临床怎么用
- 作者认为帕博利珠单抗在黑色素瘤脑转移中有活性、毒性可接受且缓解持久。
- 作者指出需要多学科协作以优化管理脑转移患者,包括考虑对大的或有症状病灶进行放疗,而本试验排除了此类病灶。
- 作者认为脑转移与颅外缓解一致支持使用帕博利珠单抗治疗小的无症状脑转移。
局限性
- 8例患者(35%)因进展或需放疗未达方案评估扫描,无法评估脑转移缓解。
- 本试验排除了需皮质类固醇、大的或有症状的脑转移病灶。
- 3例不可评估患者中1例出血、2例因病灶周围水肿症状需放射外科治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pembrolizumab is active in melanoma, but activity in patients with untreated brain metastasis is less established. We present long-term follow-up of pembrolizumab-treated patients with new or progressing brain metastases treated on a phase II clinical trial ( ClinicalTrials.gov identifier: NCT02085070). PATIENTS AND METHODS: We enrolled 23 patients with melanoma with one or more asymptomatic, untreated 5- to 20-mm brain metastasis not requiring corticosteroids; 70% of patients had prior systemic therapy. Pembrolizumab was administered for up to 24 months. Brain metastasis response, the primary end point, was assessed by modified Response Evaluation Criteria in Solid Tumors (RECIST). Pretreatment tumors were analyzed for T-cell infiltrate and programmed death ligand 1. RESULTS: Six patients (26%) had a brain metastasis response. Eight patients (35%) did not reach a protocol evaluation scan and were unevaluable for brain metastasis response as a result of progression or need for radiation. Brain metastasis and systemic responses were concordant, with all ongoing at 24 months. The median progression-free and overall survival times were 2 and 17 months, respectively. Eleven patients (48%) were alive at 24 months. This included three unevaluable patients. One of these three patients had hemorrhaged, and two had symptoms from perilesional edema requiring radiosurgery, but all three patients remained on commercial pembrolizumab more than 24 months later. None of the 24-month survivors received subsequent BRAF inhibitors. Neurologic adverse events occurred in 65% of patients; all adverse events but one were grade 1 or 2. Three patients had seizures, which were treated with anticonvulsants. Most responders had higher pretreatment tumor CD8 cell density and programmed death ligand 1 expression, whereas all nonresponders did not. CONCLUSION: Pembrolizumab is active in melanoma brain metastases with acceptable toxicity and durable responses. Multidisciplinary care is required to optimally manage patients with brain metastases, including consideration of radiation to large or symptomatic lesions, which were excluded in this trial. Two-year survival was similar to patients without brain metastasis treated with anti-programmed cell death 1 agents. Concordant brain and extracerebral responses support use of pembrolizumab to treat small, asymptomatic brain metastases.
引用
- Kluger HM, Chiang V, Mahajan A, et al. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. J Clin Oncol. 2018. PMID: 30407895. doi:10.1200/JCO.18.00204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。